Ildham Dwi Nurcahyo, . (2024) PENGARUH PEMBERIAN TOCILIZUMAB TERHADAP KADAR ENZIM TRANSAMINASE PASIEN COVID-19 DI RSUP PERSAHABATAN TAHUN 2020-2021. Skripsi thesis, Universitas Pembangunan Nasional Veteran Jakarta.
![[img]](http://repository.upnvj.ac.id/style/images/fileicons/text.png) |
Text
ABSTRAK.pdf Download (12kB) |
|
Text
AWAL.pdf Download (543kB) |
|
Text
BAB 1.pdf Restricted to Repository UPNVJ Only Download (19kB) |
|
Text
BAB 2.pdf Restricted to Repository UPNVJ Only Download (336kB) |
|
Text
BAB 3.pdf Restricted to Repository UPNVJ Only Download (100kB) |
|
Text
BAB 4.pdf Restricted to Repository UPNVJ Only Download (194kB) |
|
Text
BAB 5.pdf Download (7kB) |
|
Text
DAFTAR PUSTAKA.pdf Download (189kB) |
|
Text
RIWAYAT HIDUP.pdf Restricted to Repository UPNVJ Only Download (87kB) |
|
Text
LAMPIRAN.pdf Restricted to Repository UPNVJ Only Download (247kB) |
|
Text
HASIL PLAGIARISME.pdf Restricted to Repository staff only Download (85kB) |
|
Text
ARTIKEL KI.pdf Restricted to Repository staff only Download (492kB) |
Abstract
COVID-19 is a disease caused by infection with the SARS CoV-2 virus which can attack various organs in the human body. Interleukin-6 (IL-6) is a cytokine that plays an important role in the inflammatory and immune response to infection. Tocilizumab is a monoclonal inhibitor of the proinflammatory cytokine interleukin-6 used to treat cytokine release syndrome clinically. However, the use of tocilizumab has been associated with increased serum levels of hepatic transaminase enzymes, such as Serum Glutamate Pyruvate Transferase (SGPT), as well as Serum Glutamate Oxaloacetate Transferase (SGOT). Damage to the liver causes the release of these enzymes into the bloodstream, resulting in an increase in their levels in the blood and indicating impaired liver function. This study aims to evaluate the impact of tocilizumab administration on transaminase enzyme levels in COVID-19 patients. The method used was analytical observational research with a cross-sectional research design, with data collection carried out retrospectively. This research involved 14 medical records of COVID-19 patients who met the research criteria at Persahabatan Hospital in 2020-2021. The results of the analysis showed an increase in the average SGOT and SGPT levels in COVID-19 patients who received tocilizumab, however the Wilcoxon test did not find a significant effect of tocilizumab on transaminase enzyme levels in these patients at Persahabatan Hospital.
| Item Type: | Thesis (Skripsi) |
|---|---|
| Additional Information: | [No. Panggil: 2010212011] [Pembimbing 1: Dhigna Luthfiyani Citra Pradana] [Pembimbing 2: Nurfitri Bustamam] [Penguji: Annisa Farida Muti] |
| Uncontrolled Keywords: | COVID-19, Tocilizumab, Transaminase, SGOT, SGPT |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RS Pharmacy and materia medica |
| Divisions: | Fakultas Kedokteran > Program Studi Farmasi (S1) |
| Depositing User: | ILDHAM DWI NURCAHYO |
| Date Deposited: | 16 Aug 2024 08:47 |
| Last Modified: | 13 Sep 2024 02:45 |
| URI: | http://repository.upnvj.ac.id/id/eprint/33178 |
Actions (login required)
 |
View Item |